BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B

Phenytoin

An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs.

300+ PubMed studies analyzed · 11 RCTs · Evidence Score: 47.3

Research Domains

Phenytoin has been studied across 20 research domains including 🧠 Focus & Attention, 🫁 Liver & Detox, 🔬 Oncology, 😴 Sleep, ✨ Skin & Hair. The primary research focus is 🧠 Focus & Attention with 10% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Phenytoin, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Lamotrigine
7 shared targets
Phenobarbital
7 shared targets
Finasteride
9 shared targets
propyl
7 shared targets
Carmustine
6 shared targets
Ethanolamine
6 shared targets
Secologanin
7 shared targets
Niacin
7 shared targets
Piperonyl
8 shared targets
Nateglinide
5 shared targets
Loading evidence profile...

This evidence profile for Phenytoin is generated deterministically from 300 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.